New #Stocks to Watch -Biotech (NasdaqGS: $ERAS) (Nasdaq: $TCRX) (Nasdaq: $HCWB), Mining (CSE: $GMR.C) (CSE: $ATHA.C) Cannabis (CSE: $XBRA.C)
Point Roberts WA, Delta BC, October 22, 2021 –
(Investorideas.com Newswire) Investorideas.com, a global news source and
expert investing resource, announces its weekly roundup of stocks to watch in
Biotech, Mining and Cannabis. Today’s
stocks have been added to our lists of free stock directories in each sector.
Read this in full at https://www.investorideas.com/news/2021/main/10221Stocks.asp
The newest biotech companies are all recent Nasdaq
IPOs focusing on cancer therapies, kidney disease, Alzheimer’s, diseases of the
skin and infectious diseases.
The latest mining companies are all CSE-listed with
operations in North America.
The newest cannabis company is an
international cannabis company that includes infused beverages.
New Stocks added to Biotech Stocks Directory:
Erasca,
Inc. (NasdaqGS:ERAS) At
Erasca, our name is our mission: To erase cancer. We are a clinical-stage
precision oncology company singularly focused on discovering, developing, and
commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Our company was co-founded by leading pioneers in precision oncology and RAS
targeting to create novel therapies and combination regimens designed to
comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We
have assembled what we believe to be the deepest RAS/MAPK pathway-focused
pipeline in the industry. We believe our team’s capabilities and experience,
further guided by our scientific advisory board which includes the world’s
leading experts in the RAS/MAPK pathway, uniquely position us to achieve our
bold mission of erasing cancer.
TScan
Therapeutics, Inc. (Nasdaq:TCRX) is
a biopharmaceutical company focused on the development of T-cell receptor (TCR)
engineered T cell therapies (TCR-T) for the treatment of patients with cancer.
The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101,
are in development for the treatment of patients with hematologic malignancies
to eliminate residual leukemia and prevent relapse after hematopoietic stem
cell transplantation. The company is also developing multiplexed TCR-T therapy
candidates for the treatment of various solid tumors.
HCW
Biologics Inc. (Nasdaq: HCWB) is
a transformative immunotherapy company that focuses on inflammaging, a state of
unresolved inflammatory responses and chronic inflammation. The Company is
developing novel immunotherapies designed to improve health by disrupting the
link between chronic, low-grade inflammation and age-related diseases such as
cancer, cardiovascular diseases, diabetes, neurodegenerative diseases and
autoimmune diseases. HCW uses its TOBI™ discovery platform to generate
designer, novel multi-functional fusion molecules with immunotherapeutic
properties for the treatment of inflammaging. Two of HCW Biologics lead
inventions via TOBI™ include molecules HCW9218 and HCW9302, both currently undergoing
IND-enabling studies.
Imago BioSciences, Inc. (Nasdaq: IMGO) is
a clinical-stage biopharmaceutical company discovering and developing novel
small molecule product candidates that target lysine-specific demethylase 1
(LSD1), an enzyme that plays a central role in the production of blood cells in
the bone marrow. Imago is focused on improving the quality and length of life
for patients with cancer and bone marrow diseases. Bomedemstat, an orally
available, small molecule inhibitor of LSD1, is the lead product candidate
discovered by Imago for the treatment of certain myeloproliferative neoplasms
(MPNs), a family of related, chronic cancers of the bone marrow. Imago is
evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase
2 clinical trials for the treatment of essential thrombocythemia (NCT04254978)
and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast
Track Designation for the treatment of ET and MF, European Medicines Agency
(EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines
(PRIME) Designation by the EMA for the treatment of MF.
Unicycive
Therapeutics, Inc. (Nasdaq: UNCY) is
a biotechnology company developing novel treatments for kidney diseases.
Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being
developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected
new chemical entity in late preclinical development for the treatment of acute kidney
injury.
Transcode Therapeutics, Inc. (Nasdaq: RNAZ) is
an emerging RNA oncology company created on the belief that cancer can be
defeated through the intelligent design and effective delivery of RNA
therapeutics. The Company has created a platform of drug candidates designed to
target a variety of tumor types with the objective of significantly improving
patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is
focused on treating metastatic cancer, which causes approximately 90% of all
cancer deaths representing over nine million deaths per year worldwide. The
Company believes that TTX-MC138 has the potential to produce regression without
recurrence in a range of cancers, including breast, pancreatic, ovarian and
colon cancer, glioblastomas and others. The Company’s other drug candidates,
TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting
PD-L1 and Lin28b, respectively. The Company is also developing diagnostic
products related to its planned therapeutics business.
Acumen
Pharmaceuticals, Inc. (Nasdaq: ABOS)
headquartered in Charlottesville, VA, with clinical operations based in Carmel,
IN, is a clinical stage biopharmaceutical company developing a novel
disease-modifying approach to treat Alzheimer’s disease. Acumen’s scientific
founders pioneered research on AβOs, which a growing body of evidence indicates
are primary triggers of Alzheimer’s disease pathology. Acumen is currently
focused on advancing its investigational immunotherapy drug, ACU193, a
humanized monoclonal antibody that selectively targets toxic AβOs in a Phase I
clinical trial involving early Alzheimer’s disease patients.
Dermata
Therapeutics, Inc. (Nasdaq:DRMA) is
a clinical-stage biotechnology company focusing on the treatment of medical and
aesthetic skin conditions. The Company's lead product candidate, DMT310, is the
first product candidate being developed from its Spongilla technology platform.
DMT310 is a once-weekly topical product candidate derived from a naturally
sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is
currently under clinical development for the treatment of acne, psoriasis, and
rosacea. Our second product candidate, DMT410, uses our Spongilla technology as
a new method for topical intradermal delivery of botulinum toxin for the
treatment of multiple aesthetic skin conditions. Dermata is headquartered in
San Diego, California.
Eliem Therapeutics, Inc. (Nasdaq: ELYM) is
a clinical-stage biotechnology company focused on developing novel therapies
for neuronal excitability disorders to address unmet needs in chronic pain,
psychiatry, epilepsy and other disorders of the peripheral and central nervous
systems. These disorders often occur when neurons are overly excited or
inhibited, leading to an imbalance, and our focus is on restoring homeostasis.
We are developing a pipeline of clinically differentiated product candidates
focused on validated mechanisms of action with broad therapeutic potential to
deliver improved therapeutics for patients with these disorders. Eliem channels
its experience, energy, and passion for improving patients’ quality of life to
fuel our efforts to develop life-changing novel therapies. At its core, the
Eliem team is motivated by the promise of helping patients live happier, more
fulfilling lives.
Adagio Therapeutics, Inc. (Nasdaq: ADGI) is
a clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of antibody-based solutions for infectious
diseases with pandemic potential. The company’s portfolio of antibodies has
been optimized using Adimab’s industry-leading antibody engineering
capabilities and is designed to provide patients and clinicians with a powerful
combination of potency, breadth, durable protection (via half-life extension),
manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2
antibodies includes multiple, non-competing broadly neutralizing antibodies
with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing
capacity for the production of ADG20 with third-party contract manufacturers
through the completion of clinical trials and, if approved by regulatory
authorities, through initial commercial launch.
ABVC
BIOPHARMA, INC. (Nasdaq: ABVC) is
a clinical-stage biopharmaceutical company focused on development of
therapeutic solutions in oncology/hematology, the central nervous system (CNS),
ophthalmology, and medical devices related to these fields. Its current
pipeline features six drugs and a medical device, ABV-1701/Vitargus®. For its
drug products, it is focused on conducting proof-of-concept trials through
Phase II of clinical development at world-famous research institutions
including Stanford University, University of California at San Francisco, and
Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct
clinical trials through Phase III at various locations throughout the world.
Tyra Biosciences, Inc. (Nasdaq: TYRA) is
a precision oncology company focused on developing purpose-built therapies to
overcome tumor resistance and improve outcomes for patients with cancer. Tyra
is using its proprietary SNÅP platform, which is optimized to enable rapid and
precise refinement of structural design through iterative molecular SNÅPshots,
in order to generate next-generation product candidates that are specifically
designed to address acquired drug resistance and provide alternative treatment
options. Tyra is initially focused on developing a pipeline of selective
inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are
altered in approximately 7% of all cancers. Tyra's lead product candidate,
TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on
patients with bladder cancer.
DICE Therapeutics, Inc. (Nasdaq: DICE) is
a biopharmaceutical company leveraging its proprietary technology platform to
build a pipeline of novel oral therapeutic candidates to treat chronic diseases
in immunology and other therapeutic areas. DICE is initially focused on
developing oral therapeutics against well-validated targets in immunology, with
the goal of achieving comparable potency to their systemic biologic
counterparts, which have demonstrated the greatest therapeutic benefit to date
in these disease areas. The Company’s DELSCAPE platform is designed to discover
selective oral small molecules with the potential to modulate protein-protein
interactions (PPIs) as effectively as systemic biologics. DICE’s lead
therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory
signaling molecule, interleukin-17 (IL-17), which is a validated drug target
implicated in a variety of immunology indications. DICE is also developing oral
therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the
treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis,
respectively.
New stocks added to Mining Stocks Directory:
Brascan Gold Inc. (CSE: BRAS) is a gold exploration issuer
based in Vancouver, BC. The Company holds an option over the Vulcan Property,
located in the Fort Steele Mining Division in southeastern BC.
Gelum Resources Ltd. (CSE: GMR) is a company focused on mineral exploration in
British Columbia. Its principal project is the Eldorado Gold Property located
in the Bralorne-Bridge River Gold district in south-central British Columbia.
Athena Gold Corporation (CSE: ATHA) is engaged in the business of mineral exploration
and the acquisition of mineral property assets. Its objective is to locate and
develop economic precious and base metal properties of merit and to conduct its
exploration program on the Excelsior Springs Project, located in Esmeralda
County, Nevada, approximately 45 miles southwest of Goldfield, Nevada.
New Stocks added to Cannabis Stocks Directory:
Xebra Brands Ltd. (CSE: XBRA) is an international cannabis
cultivation and product company with global brands and intellectual property.
Xebra’s products range from wellness to leisure, and include beverages.
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news,
third party stock research, guest posts and original articles and podcasts in
leading stock sectors. Learn about
investing in stocks and get investor ideas in cannabis, crypto, AI and IoT,
mining, sports biotech, water, renewable energy, gaming and more. Investor
Idea’s original branded content includes podcasts and columns : Crypto
Corner , Play by Play sports and
stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move
podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye
Podcast.
Learn about investing in
stocks and sector trends with our news alerts, articles, podcasts and videos, looking
at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable
energy and more. Investor Idea's original branded content includes the following
podcasts and columns: Crypto
Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.
Public companies within the
sectors we cover use our news and content services to
tell their story to interested investors. Paid for content is
disclosed.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure is posted for each compensated news release, content published
/created if required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions. More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news
services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media,
podcast and ticker tag services at Investorideas.com
https://www.investorideas.com/Investors/Services.asp
Learn more about advertising and guest posts
https://www.investorideas.com/Advertise/
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club
https://www.investorideas.com/membership/
Contact
Investorideas.com
800 665 0411
